Advaxis Story

<div class='circular--portrait' style='background:#8B008B;color: #ffffff;font-size:3em;'>ADX</div>
ADXS -- USA Stock  

USD 0.61  0.03  4.69%

Advaxis is scheduled to announce its earnings tomorrow. While many of us are getting excited about healthcare space, we are going to sum up the feasibility of buying Advaxis. We will evaluate if Advaxis shares are reasonably priced given the latest economic outlook.
Published over three months ago
View all stories for Advaxis | View All Stories
Our latest take on Advaxis (NASDAQ:ADXS) analyst consensus
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Advaxis has an asset utilization ratio of 0.15 percent. This connotes that the company is making $0.001538 for each dollar of assets. An increasing asset utilization means that Advaxis is more efficient with each dollar of assets it utilizes for everyday operations.
What is the right price you would pay to acquire a share of Advaxis? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated. Please read more on our stock advisor page.

Watch out for price decline

Please consider monitoring Advaxis on a daily basis if you are holding a position in it. Advaxis is trading at a penny-stock level, and the possibility of delisting is much higher compared to other equities. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Advaxis stock to be traded above the $1 level to remain listed. If Advaxis stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

How important is Advaxis's Liquidity

Advaxis financial leverage refers to using borrowed capital as a funding source to finance Advaxis ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Advaxis financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Advaxis's total debt and its cash.

How Advaxis utilizes its cash?

To perform a cash flow analysis of Advaxis, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Advaxis is receiving and how much cash it distributes out in a given period. The Advaxis cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Advaxis Net Cash Flow from Operations is relatively stable at the moment as compared to the past year. Advaxis reported last year Net Cash Flow from Operations of (32.52 Million)

Is Advaxis a risky opportunity?

Let's check the volatility. Advaxis is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Advaxis (NASDAQ:ADXS) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. buying a share of an Advaxis stock makes you a part-owner of that company.

Will Advaxis continue to go crazy?

Treynor ratio is down to 62.36. It may connote a possible volatility fall. Advaxis exhibits very low volatility with skewness of -1.29 and kurtosis of 10.25. However, we advise investors to further study Advaxis technical indicators to make sure all market info is available and is reliable. Advaxis is a potential penny stock. Although Advaxis may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Advaxis. We encourage investors to look for the signals such us email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on this equity instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of an artificial hype usually unable to maintain its increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.

Our Takeaway on Advaxis Investment

While some other entities in the biotechnology industry are either recovering or due for a correction, Advaxis may not be performing as strong as the other in terms of long-term growth potentials. The inconsistency in the assessment between current Advaxis valuation and our trade advice on Advaxis is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Advaxis.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Advaxis. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to